ZYUS Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug
Paving the way for evidence-based solutions in cancer pain management with its lead drug product, Trichomylin® softgel capsules
SASKATOON, Saskatchewan, May 22, 2025--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce it is in the process of finalizing site initiation for the initial locations to be used in its Phase 2 UTOPIA (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial.
The Phase 2 UTOPIA clinical trial will consist of Phase 2A ("UTOPIA-1") and Phase 2B ("UTOPIA-2). UTOPIA-1 is a single-arm proof-of-concept study to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in humans with advanced cancer and moderate to severe cancer-related pain. Insights gained from UTOPIA-1 will guide the strategy for UTOPIA-2, which will be a randomized, placebo-controlled trial that will further assess safety and efficacy in a larger patient population.
Patient enrollment for UTOPIA-1 is expected to begin in early June 2025, across multiple sites in Canada, with interim data from UTOPIA-1 anticipated mid-summer 2025.
ZYUS' announcement comes at a time of growing global recognition of the untapped potential of cannabinoids in oncology. A meta-analysis of medial cannabis outcomes and associations with cancer published in Frontiers in Oncology on April 14, 2025, analyzed over 10,000 peer-reviewed studies encompassing 39,767 data points. The findings revealed a "strong consensus" supporting cannabinoids for managing cancer-related symptoms. While researchers highlight the need for further research to assess the full therapeutic potential of cannabinoids, the findings signal a critical shift in the scientific conversation. This emerging body of evidence reinforces the importance of rigorous clinical research, product purity and consistency, and reinforces ZYUS' commitment to advancing evidence-based cannabinoid therapies.
"As we finalize site initiation for UTOPIA-1, we are proud to advance clinical development of Trichomylin® softgel capsules," said Brent Zettl, President and CEO of ZYUS. "Our research aims to bridge the gap between conventional treatments like opioids and NSAIDs, and deliver an alternative, evidence-based pharmaceutical option for cancer pain. This trial is a pivotal step in our journey to improve patient outcomes and quality of life."
About ZYUS Life Sciences Corporation
ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit www.zyus.com or follow us on X @ZYUSCorp.
Cautionary Note Regarding Forward-Looking Statements
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, use UTOPIA-1 to guide the strategy for UTOPIA-2, begin patient enrollment in June 2025 and obtain interim data respecting UTOPIA-1 by mid-summer 2025. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates, introduce products that act as alternatives to current pain management therapies such as opioids, use UTOPIA-1 to guide the strategy for UTOPIA-2 begin patient enrollment in June 2025 and obtain interim data respecting UTOPIA-1 by mid-summer 2025 are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250522640382/en/
Contacts
For more information, please contact:
ZYUS Media Inquiriesmedia@zyus.com 1-833-651-7723
ZYUS Investor Relationsinvestors@zyus.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
3 hours ago
- Politico
Louisiana hospitals warn Mike Johnson of 'devastation' from megabill
Senate Republicans released updated megabill text late Friday that would make sharp cuts to the Inflation Reduction Act's solar and wind tax credits after a late-stage push by President Donald Trump to crack down further on the incentives. The text would require solar and wind generation projects seeking to qualify for the law's clean electricity production and investment tax credits to be placed in service by the end of 2027 — significantly more restrictive than an earlier proposal by the Senate Finance Committee that tied eligibility to when a project begins construction. The changes came after Trump urged Senate Majority Leader John Thune to crack down on the wind and solar credits and align the measure more closely with reconciliation text, H.R.1, that passed the House, as POLITICO reported earlier on Friday. The changes are likely to put some moderate GOP senators, who have backed a slower schedule for sunsetting those incentives, in a tough position. They'll be forced to choose between rejecting Trump's agenda or allowing the gutting of tax credits that could lead to canceled projects and job losses in their states — something renewable energy advocates are also warning about. 'We are literally going to have not enough electricity because Trump is killing solar. It's that serious,' Sen. Brian Schatz (D-Hawaii) responded on X early Saturday. 'We need a bunch of new power on the grid, and nothing is as available as solar. Everything else takes a while. Meantime, expect shortages and high prices. Stupid.' The revised text would retain the investment and production tax credits for baseload sources, such as nuclear, geothermal, hydropower or energy storage, as proposed in the Finance Committee's earlier proposal. But it would make other significant changes, including extending a tax credit for clean hydrogen production until 2028. The panel's earlier proposal would have eliminated the credit after this year. And despite vocal lobbying by the solar industry, the proposal would maintain an abrupt cut to the tax incentive supporting residential solar power. The committee's earlier proposal would have eliminated that credit six months after the enactment of the bill; now the updated draft proposes repealing it at the end of this year. It would also deny certain wind and solar leasing arrangements from accessing the climate law's clean electricity investment and production tax credits, but, in a notable change, removed earlier language specifically disallowing rooftop solar. And it would move up the timeline for certain rules barring foreign entities of concern from accessing those credits. The bill would move up the termination date for electric vehicle tax credits to Sept. 30, compared to six months after enactment in the earlier Finance text. The credit for EV chargers would extend through June 2026. The new text also provides a bonus incentive for advanced nuclear facilities built in communities with high levels of employment in the nuclear industry. And the bill makes metallurgical coal eligible for the advanced manufacturing production tax credit through 2029. Sam Ricketts, co-founder of S2 Strategies, a clean energy policy consulting group, said the new draft is going to 'screw' ratepayers, kill jobs and undermine U.S. economic competitiveness. 'All just to give fossil fuel executives more profits,' he said. 'Or to own the libs. Insanity.' Josh Siegel contributed to this report.
Politico
3 hours ago
- Politico
Elon Musk renews megabill attacks
Senate Republicans released updated megabill text late Friday that would make sharp cuts to the Inflation Reduction Act's solar and wind tax credits after a late-stage push by President Donald Trump to crack down further on the incentives. The text would require solar and wind generation projects seeking to qualify for the law's clean electricity production and investment tax credits to be placed in service by the end of 2027 — significantly more restrictive than an earlier proposal by the Senate Finance Committee that tied eligibility to when a project begins construction. The changes came after Trump urged Senate Majority Leader John Thune to crack down on the wind and solar credits and align the measure more closely with reconciliation text, H.R.1, that passed the House, as POLITICO reported earlier on Friday. The changes are likely to put some moderate GOP senators, who have backed a slower schedule for sunsetting those incentives, in a tough position. They'll be forced to choose between rejecting Trump's agenda or allowing the gutting of tax credits that could lead to canceled projects and job losses in their states — something renewable energy advocates are also warning about. 'We are literally going to have not enough electricity because Trump is killing solar. It's that serious,' Sen. Brian Schatz (D-Hawaii) responded on X early Saturday. 'We need a bunch of new power on the grid, and nothing is as available as solar. Everything else takes a while. Meantime, expect shortages and high prices. Stupid.' The revised text would retain the investment and production tax credits for baseload sources, such as nuclear, geothermal, hydropower or energy storage, as proposed in the Finance Committee's earlier proposal. But it would make other significant changes, including extending a tax credit for clean hydrogen production until 2028. The panel's earlier proposal would have eliminated the credit after this year. And despite vocal lobbying by the solar industry, the proposal would maintain an abrupt cut to the tax incentive supporting residential solar power. The committee's earlier proposal would have eliminated that credit six months after the enactment of the bill; now the updated draft proposes repealing it at the end of this year. It would also deny certain wind and solar leasing arrangements from accessing the climate law's clean electricity investment and production tax credits, but, in a notable change, removed earlier language specifically disallowing rooftop solar. And it would move up the timeline for certain rules barring foreign entities of concern from accessing those credits. The bill would move up the termination date for electric vehicle tax credits to Sept. 30, compared to six months after enactment in the earlier Finance text. The credit for EV chargers would extend through June 2026. The new text also provides a bonus incentive for advanced nuclear facilities built in communities with high levels of employment in the nuclear industry. And the bill makes metallurgical coal eligible for the advanced manufacturing production tax credit through 2029. Sam Ricketts, co-founder of S2 Strategies, a clean energy policy consulting group, said the new draft is going to 'screw' ratepayers, kill jobs and undermine U.S. economic competitiveness. 'All just to give fossil fuel executives more profits,' he said. 'Or to own the libs. Insanity.' Josh Siegel contributed to this report.
The Hill
3 hours ago
- The Hill
Senate's ‘big, beautiful bill' faces serious headwinds in the House
The Senate's version of the 'big, beautiful bill' is facing serious headwinds in the House with at least six House Republicans telling The Hill they are currently a 'no' on the framework, a daunting sign for GOP leadership as the Senate races towards a vote. Those six House Republicans, some of whom requested anonymity, are enough opposition to tank the package, as GOP leaders grapple with a razor-thin majority. Rep. Thomas Massie (R-Ky.), who was one of two GOP lawmakers to oppose the House version of the bill last month, is also likely to oppose the Senate's edition, deepening the pocket of resistance in the lower chamber. Republicans can only afford to lose three votes and still clear the legislation, assuming full attendance and united Democratic opposition. 'I support the reasonable provisions in H.R. 1 that protect Medicaid's long-term viability and ensure the program continues to serve our most vulnerable, but I will not support a final bill that eliminates vital funding streams our hospitals rely on, including provider taxes and state directed payments, or any provisions that punish expansion states,' Rep. David Valadao (R-Calif.) wrote in a statement on Saturday. 'President Trump was clear when he said to root out our waste, fraud, and abuse without cutting Medicaid and I wholeheartedly agree,' he continued. 'I urge my Senate colleagues to stick to the Medicaid provisions in H.R. 1 — otherwise I will vote no.' Rep. Jeff Van Drew (R-N.J.) told The Hill that he is also opposed to the bill because of the Medicaid provider tax provision. Rep. Young Kim (R-Calif.) is currently a 'no' on the measure because of the Medicaid language, rollback of solar energy credits and public lands provisions, a source familiar with the matter told The Hill. Rep. Nick LaLota (R-N.Y.), meanwhile, told The Hill that he is against the current version of the package because of the state and local tax (SALT) deduction cap proposal. The legislation would increase the currently $10,000 SALT cap to $40,000 for individuals making $500,000 or less for five years, then snap back to the original number. 'While I support the President's broader agenda, how could I support the same unfair $10k SALT cap I've spent years criticizing?' LaLota said. 'A permanent $40k deduction cap with income thresholds of $225k for single filers and $450k for joint filers would earn my vote.' It is not, however, just moderates who are signaling issues with the Senate bill: Rep. Chip Roy (R-Texas), a member of the conservative House Freedom Caucus, posted an ominous message on X that suggested he was not pleased with the package. 'I will not negotiate via X. But it's important to know that jamming us with a bill before we've had any chance to review the implications of major changes & re-writes, fluid scores, a high likelihood of violating the house framework (deficits) , & tons of swamp buy-offs is bad,' he wrote. The opposition is rising to the surface as Senate Republicans inch closer to holding an initial vote on the 'big, beautiful bill,' which would officially kick off the consideration process and eventually tee up a final vote in the House. It remains unclear, however, if Senate GOP leaders have the votes to move forward. If the motion to proceed passes by a simple majority, the chamber would hold a series of unlimited amendment votes called a vote-a-rama, which could result in changes to the measure. Senate GOP leaders are also still talking to holdouts and could make changes to the bill as written. In the meantime, House Republicans — beginning to review the revised Senate text unveiled overnight — are expressing resistance to the measure, prompting serious questions about whether top GOP lawmakers will be able to enact the legislation by their self-imposed July 4 deadline. Speaker Mike Johnson (R-La.) convened a call with the House Republican Conference Saturday afternoon and urged lawmakers to keep their concerns with the Senate bill private, and instead speak directly with their senators and the White House, two sources told The Hill. Senate Majority Leader Steve Scalise (R-La.) told members that it is unlikely they will have to return to Washington on Monday, the sources said. Tuesday or Wednesday is more realistic, he told lawmakers. One source told The Hill that the call was brief and leadership did not take questions. The main qualm among House Republicans appears to be the Medicaid language in the bill. The Senate's legislation includes a proposal that would effectively cap provider taxes at 3.5 percent by 2031, down from the current 6 percent, but only for the states that expanded Medicaid under the Affordable Care Act. The decrease was initially supposed to begin in 2027, with a 0.5 percent phase down annually, but Senate Republicans overnight changed the text to delay the implementation to 2028. The upper chamber also inserted a provision to create a $25 billion rural hospital relief fund that would be distributed over five years to assuage those concerns. The changes, however, do not seem to be solving all of the GOP's problems, with House Republicans still voicing opposition to the language. Aside from Medicaid, the Senate bill's rollback of green-energy tax credits is an issue for some House Republicans. The revised legislation for the upper chamber slashes tax incentives for wind and solar energy and adds a new tax on future wind and solar projects. Rep. Don Bacon (R-Neb.) would not say how he plans to vote on the bill, but signaled that he is not happy with the Medicaid provisions and green-energy tax credit language. 'Instead of improving the Medicaid and energy portions of [the] House bill it appears the Senate went backwards,' he told The Hill.
